Clinerion Partners with Dresden International University
The Master’s Program in Clinical Research (MPCR) at Dresden International University (DIU) will now offer lectures in the generation of RWE from Real World Data (RWD), for the first time in such a course in the world.
The Real World Data for the course will be sourced from a subset of the de-identified electronic health records of patients in Clinerion’s hospital network. DIU Master’s students will gain access to Patient Network Explorer, Clinerion’s platform for secure, cloud-based query of remote, de-identified hospital patient data.
The collaboration will begin in August 2019, and involve students of the 2019/2020 intake. DIU Master’s students typically have a background in fields such as oncology, neurology, cardiology and nephrology, among others. The Master’s students will already have been trained in clinical trial concepts, including study phases, trial design, biostatistics and data analysis, and scientific presentation, and will commence their Master’s research work, using Clinerion RWD, in the Fall Semester of 2020. Each of these international students will choose their own topic of research; PNEx provides access to five dimensions of patient data – demographics, prescribed medication, laboratory results, diagnosis and treatments – and can therefore support the students, independent of field or therapeutic area, as long as patient data has been recorded.
Students will learn how to identify student cohorts based on international terminologies, how to test feasibility and improve study protocols with real-time feedback. With an optimized set of inclusion and exclusion criteria, students will be able to access and analyze their respective patient cohort data for their Master’s thesis. Results will be presented at international meetings and published in indexed, peer-reviewed scientific journals.
“We elected to partner with Clinerion because they are at the cutting edge of the use of RWD for clinical research,” says Course Director, Dr. Ben Illigens. “Clinerion data is secure, transparent, scalable and international and therefore a perfect fit for our program and for our students’ needs. We are looking forward to presenting the results of this novel collaboration.”
“Clinerion is laser-focused on the well-being of patients and we are pleased to support the academic development of clinical students for the betterment of patient care around the world,” says Ian Rentsch, CEO of Clinerion.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
